Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,952

Document Document Title
WO/2019/139899A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139907A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139902A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/139900A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/136145A1
The invention provides methods utilizing Prins reaction in the preparation of compounds that may be useful as intermediates in the synthesis of halichondrin macrolides and analogs thereof. The invention also provides compounds that may b...  
WO/2019/132484A1
The present specification relates to a heterocyclic compound represented by formula 1 and an organic light-emitting device comprising the same.  
WO/2019/121108A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices. According to the invention, the organic compound consists of - one first chemical moiety with a structure of formula I, and - one ...  
WO/2019/126731A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...  
WO/2019/126733A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, a...  
WO/2019/121602A1
The present invention relates to a cyanoaryl substituted compound of formula (I), (I) wherein m is 0-4; R2, R3, R4 and R5 are selected from hydrogen, chlorine, bromine and C6-C24-aryl, which carries one to three cyano; each R1 independen...  
WO/2019/126121A1
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.  
WO/2019/121112A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices. According to the invention, the organic compound consists of - a first chemical moiety with a structure of formula I, - one second...  
WO/2019/126122A1
The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.  
WO/2019/119207A1
Provided are compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.  
WO/2019/123375A1
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use therof for treatment of a neurological disorder.  
WO/2019/126242A1
Disclosed are compounds of Formula (I) or salts thereof, wherein G, R1, R5, R7, R8, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pha...  
WO/2019/120263A1
The present invention relates to an organic mixture and an application thereof in organic electronic devices. The organic mixture comprises a spirofluorene organic compound containing a fused heterocyclic ring and an aromatic fused heter...  
WO/2019/126730A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...  
WO/2019/126082A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...  
WO/2019/120079A1
The present invention provides a thioxoimidazole dione compound as shown in formula (I). The compound can act as an androgen receptor antagonist and can be used to prepare a drug for treating an androgen receptor-related disease or disor...  
WO/2019/123378A1
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use therof for treatment of a neurological disorder.  
WO/2019/121341A1
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety with a structure of formula I, and - two second che...  
WO/2019/115447A1
The invention relates to an organic compound, in particular for the use in optoelectronic devices. According to the invention, the organic compound has • - a first chemical moiety with a structure of formula (I), Formula (I) and • - ...  
WO/2019/114666A1
The present invention relates to a bioactive conjugate, a preparation method therefor, and use thereof. In particular, the present invention relates to a novel type of bioactive molecular conjugates obtained by improving the coupling of ...  
WO/2019/118973A1
The present invention relates to novel compounds of formula (I) or formula (Ia), pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for pre...  
WO/2019/115586A1
The present invention relates to novel compounds which act as modulators of indoleamine 2,3-dioxygenase (IDOl) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dio...  
WO/2019/118612A1
The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocel...  
WO/2019/110352A1
The present invention discloses compounds according to Formula (I), wherein R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions compris...  
WO/2019/111980A1
The present invention provides a compound having an exceptional inhibitory action on EP300 and/or CREBBP histone acetyl transferase, or a pharmaceutically acceptable salt thereof. A compound represented by formula (1) or a pharmaceutical...  
WO/2019/113359A1
The present invention relates to compounds of Formula (la) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof a...  
WO/2019/108591A1
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof (1) wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contempl...  
WO/2019/107739A1
Disclosed are: a compound represented by chemical formula 1; an organic electronic device comprising a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode; and an electronic appa...  
WO/2019/105913A1
The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.  
WO/2019/101746A1
The invention relates to an organic compound, in particular for the use in optoelectronic devices. According to the invention, the organic compound has - a first chemical moiety with a structure of formula (I), and - two second chemical ...  
WO/2019/101132A1
Disclosed in the present invention are a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a ca...  
WO/2019/103060A1
The present invention addresses the problem of providing a drug to be used to prevent or treat obesity or to prevent or treat type 2 diabetes. The means for solution according to the present invention is a compound represented by general...  
WO/2019/104285A1
Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, inclu...  
WO/2019/101594A1
The invention relates to an organic compound, in particular for the application in optoelectronic devices.According to the invention, the organic compound consists of -a first chemical moiety with a structure of formula I, Formula I and ...  
WO/2019/099307A1
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...  
WO/2019/095066A1
The present disclosure relates to compounds, methods and uses thereof for targeting tubulin, ch-TOG, Aurora A kinase, TPX2, Cdk5rap2 and/or ASPM and for the treatment of cancer in a subject. For example, the compounds can comprise compou...  
WO/2019/099336A1
Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or...  
WO/2019/099669A1
The present invention relates to single enantiomer isothiazoline compounds of formula (I) and methods of synthesizing the compounds. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests ...  
WO/2018/227058A9
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2019/098211A1
The present invention provides: a compound (In the formula: R1 and R2 represent a hydrogen atom, a C1-4 alkyl, or the like; n represents 1 or 2; ring A represents a C6-10 aromatic carbon ring or the like; R3, R4 and R5 represent a hydrog...  
WO/2019/098765A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2019/090920A1
A photochromic nano-composite microsphere and a coating material and a photochromic optical material prepared therefrom, and a coating using the coating material. The photochromic nano-composite microsphere has a three-layer composite co...  
WO/2019/088447A1
Disclosed are: an organic electroluminescent element including a compound represented by chemical formula 1, a first electrode, a second electrode, and an organic material layer between the first electrode and second electrode; and an el...  
WO/2019/088561A1
The present application relates to a heterocyclic compound represented by chemical formula 1, and an organic light emitting device comprising the same.  
WO/2019/087129A1
The invention relates to compounds of formula I and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/ma...  
WO/2019/090198A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activi...  

Matches 1 - 50 out of 17,952